Latest Commercialization News

Codeifai Limited reported a 26% revenue decline to $598,497 for 2025 alongside a sharp increase in net loss to $6.22 million, driven by strategic investments and market challenges. The company’s pivot to self-service SaaS platforms, including a key acquisition post-year-end, signals a transformative but uncertain path forward.

Advanced Energy Minerals reports a sharp revenue increase alongside a substantial net loss for 2025, completing a major plant expansion and raising $44.8 million in its IPO.

Environmental Clean Technologies Limited reported a $2.58 million loss for the half-year ended December 2025, marking a strategic pivot with the acquisition of Terrajoule Pty Ltd and exclusive rights to innovative remediation technology.

Janus Electric Holdings reported a 46% increase in net loss to $4.93 million for the half-year ended December 2025, driven by rising costs despite a 33% revenue boost. The company faces funding uncertainties as it pursues key investments and operational scale-up.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Brisbane Broncos Limited has reported a robust 2025 financial year, with profit before tax soaring 35% to $11.34 million, buoyed by premiership wins in both the NRL and NRLW competitions. The club also declared a special dividend, reflecting its strong commercial and community momentum.

Synertec Corporation Limited reported a 20% increase in revenue to $10.2 million for the half-year ended 31 December 2025, alongside a 40% improvement in net loss after tax. The company’s Powerhouse renewable energy system continues to gain traction, supported by strategic partnerships and expanded manufacturing.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

Clime Investment Management reports a strong half-year operating profit surge and proposes a fully franked interim dividend, while streamlining its business to target sophisticated investors.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.